Oncolytics Biotech
ONCY
32 hedge funds and large institutions have $2.11M invested in Oncolytics Biotech in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
53% more capital invested
Capital invested by funds: $1.38M → $2.11M (+$736K)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.59% less ownership
Funds ownership: 1.86% → 1.27% (-0.59%)
3% less funds holding
Funds holding: 33 → 32 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$128K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$101K |
| 3 |
HL
HeadInvest LLC
Portland,
Maine
|
+$19.2K |
| 4 |
BAM
Brave Asset Management
Summit,
New Jersey
|
+$16.6K |
| 5 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$375K |
| 2 |
Renaissance Technologies
New York
|
-$156K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$105K |
| 4 |
VF
Virtu Financial
New York
|
-$28K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22.2K |
ONCY Hedge Fund Activity: Q2 2023 in Review
32 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2023, worth a combined $2.11M — up 53% from $1.38M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ONCY and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $128K. The largest seller was Osaic Holdings, cutting an estimated $375K.
- 32 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2023, down from 33 in Q1 2023.
- Funds reported $2.11M of Oncolytics Biotech stock for Q2 2023, up 53% quarter-over-quarter.
- 5 funds opened new Oncolytics Biotech positions in Q2 2023 and 6 closed out, a net change of -1 holder.
- The largest Oncolytics Biotech buyer in Q2 2023 was Morgan Stanley, an estimated $128K added.
- The largest Oncolytics Biotech seller in Q2 2023 was Osaic Holdings, an estimated $375K sold.
Based on aggregated 13F filings for Q2 2023.